Answers are grounded in this paper and cite their sources.
Glucagon-like peptide-1 (GLP-1) receptor agonists have evolved from agents for reducing glucose and regulating weight to become core treatment options for cardiometabolic disease. Dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, have further expanded the options. This narrative review aims to discuss the cardiovascular, renal and hepatic outcomes associated with GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. Randomised outcomes trials have shown that some GLP-1 receptor agonists can reduce major adverse cardiovascular events in selected patient groups. Semaglutide has demonstrated cardiovascular benefits in patients with overweight/obesity and existing cardiovascular disease but no diabetes. It has also shown benefits to renal outcomes in patients with type 2 diabetes and chronic kidney disease. Tirzepatide has shown benefits in patients with obesity related heart failure with preserved ejection fraction and is non-inferior to dulaglutide in reducing major cardiovascular events in type 2 diabetes with atherosclerotic cardiovascular disease. There is significant evidence for liver benefits. Phase 2 data for tirzepatide and phase 3 interim data for semaglutide have demonstrated improvements in histological features of metabolic dysfunction-associated steatohepatitis. Potential mechanisms for these benefits include improved insulin sensitivity, reduced adiposity and ectopic fat, reduced blood pressure, altered lipid metabolism, anti-inflammatory effects and renal haemodynamic changes. However, it can be difficult to isolate direct effects on specific organs, and this evidence cannot always be generalised to all drugs/individuals. This review will highlight strengths and limitations of this evidence and priority areas for future investigation.
No takes yet. Share an insight, caveat, or question.
Stanley George Soji (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: